Published in J Biol Chem on March 17, 2003
Solid-phase synthesis, characterization, and cellular activities of collagen-model Nanodiamond-peptide conjugates. Biopolymers (2015) 1.39
Molecular biology of pharmacologic vitreolysis. Trans Am Ophthalmol Soc (2005) 1.26
Selective modulation of matrix metalloproteinase 9 (MMP-9) functions via exosite inhibition. J Biol Chem (2008) 1.15
Synthesis and biological applications of collagen-model triple-helical peptides. Org Biomol Chem (2010) 1.05
Differentiation of secreted and membrane-type matrix metalloproteinase activities based on substitutions and interruptions of triple-helical sequences. Biochemistry (2007) 1.05
High throughput screening of potentially selective MMP-13 exosite inhibitors utilizing a triple-helical FRET substrate. Bioorg Med Chem (2008) 1.03
Exosite interactions impact matrix metalloproteinase collagen specificities. J Biol Chem (2011) 1.02
Triple-helical transition state analogues: a new class of selective matrix metalloproteinase inhibitors. J Am Chem Soc (2007) 1.00
MMP-12 catalytic domain recognizes triple helical peptide models of collagen V with exosites and high activity. J Biol Chem (2008) 0.97
Detection of MMP-2 and MMP-9 activity in vivo with a triple-helical peptide optical probe. Bioconjug Chem (2012) 0.96
A shift in the collagen V antigenic epitope leads to T helper phenotype switch and immune response to self-antigen leading to chronic lung allograft rejection. Clin Exp Immunol (2012) 0.94
Development of a solid-phase assay for analysis of matrix metalloproteinase activity. J Biomol Tech (2004) 0.94
Local conformation and dynamics of isoleucine in the collagenase cleavage site provide a recognition signal for matrix metalloproteinases. J Biol Chem (2010) 0.94
Release of liposomal contents by cell-secreted matrix metalloproteinase-9. Bioconjug Chem (2009) 0.93
NMR and bioinformatics discovery of exosites that tune metalloelastase specificity for solubilized elastin and collagen triple helices. J Biol Chem (2010) 0.92
Chemical biology for understanding matrix metalloproteinase function. Chembiochem (2012) 0.92
Mechanistic studies of the triggered release of liposomal contents by matrix metalloproteinase-9. J Am Chem Soc (2008) 0.91
Ultrasound enhanced matrix metalloproteinase-9 triggered release of contents from echogenic liposomes. Mol Pharm (2012) 0.90
Matrix metalloproteinase-9 is differentially expressed in nonfunctioning invasive and noninvasive pituitary adenomas and increases invasion in human pituitary adenoma cell line. Am J Pathol (2007) 0.90
Using fluorogenic peptide substrates to assay matrix metalloproteinases. Methods Mol Biol (2001) 0.88
AP-1 (Fra-1/c-Jun)-mediated induction of expression of matrix metalloproteinase-2 is required for 15S-hydroxyeicosatetraenoic acid-induced angiogenesis. J Biol Chem (2010) 0.83
Apparent tradeoff of higher activity in MMP-12 for enhanced stability and flexibility in MMP-3. Biophys J (2010) 0.83
Fluorometric immunocapture assay for the specific measurement of matrix metalloproteinase-9 activity in biological samples: application to brain and plasma from rats with ischemic stroke. Mol Brain (2013) 0.82
Comparison of metalloproteinase protein and activity profiling. Anal Biochem (2010) 0.79
The role of collagen charge clusters in the modulation of matrix metalloproteinase activity. J Biol Chem (2013) 0.79
Regulatory T cells in lung transplantation--an emerging concept. Semin Immunopathol (2011) 0.79
Evaluation of a triple-helical peptide with quenched FluorSophores for optical imaging of MMP-2 and MMP-9 proteolytic activity. Molecules (2014) 0.78
Plasmin releases the anti-tumor peptide from the NC1 domain of collagen XIX. Oncotarget (2015) 0.78
Development of a Förster resonance energy transfer assay for monitoring bacterial collagenase triple-helical peptidase activity. Anal Biochem (2014) 0.77
Near-infrared triple-helical peptide with quenched fluorophores for optical imaging of MMP-2 and MMP-9 proteolytic activity in vivo. Bioorg Med Chem Lett (2014) 0.77
Collagenolytic Matrix Metalloproteinase Activities toward Peptomeric Triple-Helical Substrates. Biochemistry (2015) 0.76
Early matrix metalloproteinase-9 inhibition post-myocardial infarction worsens cardiac dysfunction by delaying inflammation resolution. J Mol Cell Cardiol (2016) 0.76
Path to Collagenolysis: COLLAGEN V TRIPLE-HELIX MODEL BOUND PRODUCTIVELY AND IN ENCOUNTERS BY MATRIX METALLOPROTEINASE-12. J Biol Chem (2016) 0.75
Fistulising Crohn's disease: MMPs gone awry. Gut (2004) 0.75
Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res (2003) 13.22
Multi-step pericellular proteolysis controls the transition from individual to collective cancer cell invasion. Nat Cell Biol (2007) 6.15
The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. Biochim Biophys Acta (2010) 3.33
Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effects on matrix metalloproteinase inhibition: implications for reversibility of liver fibrosis. J Biol Chem (2002) 2.88
Collagenase unwinds triple-helical collagen prior to peptide bond hydrolysis. EMBO J (2004) 2.58
Progress in matrix metalloproteinase research. Mol Aspects Med (2008) 2.51
Membrane protease proteomics: Isotope-coded affinity tag MS identification of undescribed MT1-matrix metalloproteinase substrates. Proc Natl Acad Sci U S A (2004) 1.91
Engagement of collagen-binding integrins promotes matrix metalloproteinase-9-dependent E-cadherin ectodomain shedding in ovarian carcinoma cells. Cancer Res (2007) 1.90
Altered proteolytic activities of ADAMTS-4 expressed by C-terminal processing. J Biol Chem (2003) 1.87
Reappraising metalloproteinases in rheumatoid arthritis and osteoarthritis: destruction or repair? Nat Clin Pract Rheumatol (2008) 1.75
Proteases involved in cartilage matrix degradation in osteoarthritis. Biochim Biophys Acta (2011) 1.73
Proinvasive properties of ovarian cancer ascites-derived membrane vesicles. Cancer Res (2004) 1.69
Proteolytic activities of human ADAMTS-5: comparative studies with ADAMTS-4. J Biol Chem (2007) 1.66
Matrix metalloproteinases in cancer. Essays Biochem (2002) 1.65
Phenotypic plasticity of neoplastic ovarian epithelium: unique cadherin profiles in tumor progression. Clin Exp Metastasis (2008) 1.65
Matrix metalloproteinases and collagen catabolism. Biopolymers (2002) 1.64
Proteases, extracellular matrix, and cancer: a workshop of the path B study section. Am J Pathol (2004) 1.52
Matrix metalloproteinase 9 is a mediator of epidermal growth factor-dependent e-cadherin loss in ovarian carcinoma cells. Cancer Res (2008) 1.51
Membrane type 1-matrix metalloproteinase: substrate diversity in pericellular proteolysis. Semin Cell Dev Biol (2007) 1.50
The roles of substrate thermal stability and P2 and P1' subsite identity on matrix metalloproteinase triple-helical peptidase activity and collagen specificity. J Biol Chem (2006) 1.49
Structural insights into triple-helical collagen cleavage by matrix metalloproteinase 1. Proc Natl Acad Sci U S A (2012) 1.46
Regulation of collagenase activities of human cathepsins by glycosaminoglycans. J Biol Chem (2003) 1.46
Tissue inhibitor of metalloproteinases-3 induces apoptosis in melanoma cells by stabilization of death receptors. Oncogene (2003) 1.40
Cyclooxygenase-2 functions as a downstream mediator of lysophosphatidic acid to promote aggressive behavior in ovarian carcinoma cells. Cancer Res (2005) 1.39
Epidermal growth factor receptor inhibition promotes desmosome assembly and strengthens intercellular adhesion in squamous cell carcinoma cells. J Biol Chem (2004) 1.37
Angiogenesis in collagen I requires alpha2beta1 ligation of a GFP*GER sequence and possibly p38 MAPK activation and focal adhesion disassembly. J Biol Chem (2003) 1.36
Correlated structural kinetics and retarded solvent dynamics at the metalloprotease active site. Nat Struct Mol Biol (2011) 1.35
Individual Timp deficiencies differentially impact pro-MMP-2 activation. J Biol Chem (2006) 1.34
Calcium pentosan polysulfate is a multifaceted exosite inhibitor of aggrecanases. FASEB J (2008) 1.32
Molecular mechanism of type I collagen homotrimer resistance to mammalian collagenases. J Biol Chem (2010) 1.30
X-ray structure of human proMMP-1: new insights into procollagenase activation and collagen binding. J Biol Chem (2004) 1.30
Identification of specific hemopexin-like domain residues that facilitate matrix metalloproteinase collagenolytic activity. J Biol Chem (2009) 1.30
Carcinomas contain a matrix metalloproteinase-resistant isoform of type I collagen exerting selective support to invasion. Cancer Res (2010) 1.26
Cell surface collagenolysis requires homodimerization of the membrane-bound collagenase MT1-MMP. Mol Biol Cell (2006) 1.26
Microenvironmental regulation of membrane type 1 matrix metalloproteinase activity in ovarian carcinoma cells via collagen-induced EGR1 expression. J Biol Chem (2006) 1.24
Critical role of lysophospholipids in the pathophysiology, diagnosis, and management of ovarian cancer. Cancer Treat Res (2002) 1.22
The history of matrix metalloproteinases: milestones, myths, and misperceptions. Am J Physiol Heart Circ Physiol (2012) 1.22
Structural basis for matrix metalloproteinase 1-catalyzed collagenolysis. J Am Chem Soc (2012) 1.21
Tissue inhibitor of metalloproteinases-1 promotes liver metastasis by induction of hepatocyte growth factor signaling. Cancer Res (2007) 1.21
Crystal structure of an active form of human MMP-1. J Mol Biol (2006) 1.20
Matrix metalloproteinase triple-helical peptidase activities are differentially regulated by substrate stability. Biochemistry (2004) 1.20
Low density lipoprotein receptor-related protein mediates endocytic clearance of pro-MMP-2.TIMP-2 complex through a thrombospondin-independent mechanism. J Biol Chem (2004) 1.20
Selective modulation of matrix metalloproteinase 9 (MMP-9) functions via exosite inhibition. J Biol Chem (2008) 1.15
Glycosylation broadens the substrate profile of membrane type 1 matrix metalloproteinase. J Biol Chem (2003) 1.14
Functional differences of the catalytic and non-catalytic domains in human ADAMTS-4 and ADAMTS-5 in aggrecanolytic activity. J Biol Chem (2007) 1.14
TIMP-3 inhibits the procollagen N-proteinase ADAMTS-2. Biochem J (2006) 1.13
Differential inhibition of membrane type 3 (MT3)-matrix metalloproteinase (MMP) and MT1-MMP by tissue inhibitor of metalloproteinase (TIMP)-2 and TIMP-3 rgulates pro-MMP-2 activation. J Biol Chem (2003) 1.13
Expression and activity profiling of selected cysteine cathepsins and matrix metalloproteinases in synovial fluids from patients with rheumatoid arthritis and osteoarthritis. Biol Chem (2010) 1.13
Matrix metalloproteinase 1 interacts with neuronal integrins and stimulates dephosphorylation of Akt. J Biol Chem (2003) 1.11
Membrane type 1 matrix metalloproteinase is a crucial promoter of synovial invasion in human rheumatoid arthritis. Arthritis Rheum (2009) 1.11
Ovarian cancer cell detachment and multicellular aggregate formation are regulated by membrane type 1 matrix metalloproteinase: a potential role in I.p. metastatic dissemination. Cancer Res (2009) 1.10
Activation of membrane-type matrix metalloproteinase 3 zymogen by the proprotein convertase furin in the trans-Golgi network. Cancer Res (2002) 1.09
Down-regulation of integrin alpha2 surface expression by mutant epidermal growth factor receptor (EGFRvIII) induces aberrant cell spreading and focal adhesion formation. Cancer Res (2005) 1.09
TIMP-3 inhibits aggrecanase-mediated glycosaminoglycan release from cartilage explants stimulated by catabolic factors. FEBS Lett (2003) 1.08
Modulation of the membrane type 1 matrix metalloproteinase cytoplasmic tail enhances tumor cell invasion and proliferation in three-dimensional collagen matrices. J Biol Chem (2009) 1.08
Matrix metalloproteinase expression and function during fin regeneration in zebrafish: analysis of MT1-MMP, MMP2 and TIMP2. Matrix Biol (2005) 1.07
Palmitoylation at Cys574 is essential for MT1-MMP to promote cell migration. FASEB J (2005) 1.07
Calcium regulation of matrix metalloproteinase-mediated migration in oral squamous cell carcinoma cells. J Biol Chem (2002) 1.07
Polypyrimidine tract-binding protein (PTB) differentially affects malignancy in a cell line-dependent manner. J Biol Chem (2008) 1.07
Integrin regulation of beta-catenin signaling in ovarian carcinoma. J Biol Chem (2011) 1.06
Reactive site mutations in tissue inhibitor of metalloproteinase-3 disrupt inhibition of matrix metalloproteinases but not tumor necrosis factor-alpha-converting enzyme. J Biol Chem (2005) 1.05
Diverse mechanisms for activation of Wnt signalling in the ovarian tumour microenvironment. Biochem J (2011) 1.05
Differentiation of secreted and membrane-type matrix metalloproteinase activities based on substitutions and interruptions of triple-helical sequences. Biochemistry (2007) 1.05
Functional relevance of urinary-type plasminogen activator receptor-alpha3beta1 integrin association in proteinase regulatory pathways. J Biol Chem (2006) 1.04
Cell cholesterol modulates metalloproteinase-dependent shedding of low-density lipoprotein receptor-related protein-1 (LRP-1) and clearance function. FASEB J (2011) 1.03
Localizing matrix metalloproteinase activities in the pericellular environment. FEBS J (2010) 1.03
High throughput screening of potentially selective MMP-13 exosite inhibitors utilizing a triple-helical FRET substrate. Bioorg Med Chem (2008) 1.03
Proteinase suppression by E-cadherin-mediated cell-cell attachment in premalignant oral keratinocytes. J Biol Chem (2002) 1.02
Discovery of novel inhibitors of a disintegrin and metalloprotease 17 (ADAM17) using glycosylated and non-glycosylated substrates. J Biol Chem (2012) 1.02
Endorepellin, the C-terminal angiostatic module of perlecan, enhances collagen-platelet responses via the alpha2beta1-integrin receptor. Blood (2006) 1.02
Exosite interactions impact matrix metalloproteinase collagen specificities. J Biol Chem (2011) 1.02
Extracellular proteases as targets for drug development. Curr Protein Pept Sci (2009) 1.02
Catalytic properties of ADAM12 and its domain deletion mutants. Biochemistry (2007) 1.01
Contributions of the MMP-2 collagen binding domain to gelatin cleavage. Substrate binding via the collagen binding domain is required for hydrolysis of gelatin but not short peptides. Matrix Biol (2004) 1.01
Motility-related actinin alpha-4 is associated with advanced and metastatic ovarian carcinoma. Lab Invest (2008) 1.01
Mechanism of inhibition of matrix metalloproteinase-2 expression by doxycycline in human aortic smooth muscle cells. J Vasc Surg (2003) 1.01
Triple-helical transition state analogues: a new class of selective matrix metalloproteinase inhibitors. J Am Chem Soc (2007) 1.00
Shedding of discoidin domain receptor 1 by membrane-type matrix metalloproteinases. J Biol Chem (2013) 1.00
Microenvironmental regulation of ovarian cancer metastasis. Cancer Treat Res (2009) 0.99
The second dimer interface of MT1-MMP, the transmembrane domain, is essential for ProMMP-2 activation on the cell surface. J Biol Chem (2008) 0.99
The dimer interface of the membrane type 1 matrix metalloproteinase hemopexin domain: crystal structure and biological functions. J Biol Chem (2010) 0.99
Lysophosphatidic acid down-regulates stress fibers and up-regulates pro-matrix metalloproteinase-2 activation in ovarian cancer cells. Mol Cancer Res (2007) 0.99
Bisphosphonate effects on the behaviour of oral epithelial cells and oral fibroblasts. Arch Oral Biol (2010) 0.99
Defining requirements for collagenase cleavage in collagen type III using a bacterial collagen system. J Biol Chem (2012) 0.98
Polypeptide chains containing D-gamma-hydroxyvaline. J Am Chem Soc (2005) 0.98
Catalytic- and ecto-domains of membrane type 1-matrix metalloproteinase have similar inhibition profiles but distinct endopeptidase activities. Biochem J (2004) 0.98
A novel conotoxin framework with a helix-loop-helix (Cs alpha/alpha) fold. Biochemistry (2005) 0.98
Mesenchymal transformation in epithelial ovarian tumor cells expressing epidermal growth factor receptor variant III. Mol Carcinog (2006) 0.98
Modulation of triple-helical stability and subsequent melanoma cellular responses by single-site substitution of fluoroproline derivatives. Biochemistry (2002) 0.98
LRP-1-mediated endocytosis regulates extracellular activity of ADAMTS-5 in articular cartilage. FASEB J (2012) 0.98
Reactive-site mutants of N-TIMP-3 that selectively inhibit ADAMTS-4 and ADAMTS-5: biological and structural implications. Biochem J (2010) 0.97
MMP-12 catalytic domain recognizes triple helical peptide models of collagen V with exosites and high activity. J Biol Chem (2008) 0.97
Functional in vivo imaging of cysteine cathepsin activity in murine model of inflammation. Bioorg Med Chem (2010) 0.97
Microenvironmental regulation of chemokine (C-X-C-motif) receptor 4 in ovarian carcinoma. Mol Cancer Res (2010) 0.97
The interface between catalytic and hemopexin domains in matrix metalloproteinase-1 conceals a collagen binding exosite. J Biol Chem (2011) 0.97